Please login to the form below
Argenx
This page shows the latest Argenx news and features for those working in and with pharma, biotech and healthcare.
bluebird bio sells second FDA priority review voucher for $95m
The company sold its first voucher to Dutch biotech Argenx for $102m. ... The company’s first voucher was sold for $102m to Dutch biotech Argenx, which expected to use the PRV for a future marketing application for efgartigimod, its first-in-class
Latest news
-
J&J exits $1.6bn blood cancer drug licensing deal with argenx
J&J and argenx signed a deal in 2018 to develop cusatuzumab to treat haematological cancers. ... Johnson &Johnson (J&J) has pulled out of a $1.6bn licensing deal with Dutch biotech company argenx for the CD70-targeting antibody cusatuzumab.
-
Dutch biotech Argenx claims $1.8bn licensing deal with J&J
the early stage of the programme and also that Argenx is also retaining co-promotion rights in the US. ... In that market the companies have agreed to share economics 50/50 on a royalty basis, while Argenx will get double-digit sales royalties elsewhere.
-
AbbVie to develop argenx-partnered GARP-targeted immunotherapy
So with this new mechanism, argenx is hoping that its candidate can modulate the body’s own immune system to attack cancer cells. ... Our collaboration with argenx over the past two years has been productive, and we look forward to continue working
-
AbbVie adds to cancer portfolio with $9.8bn Stemcentrx deal
Since then it has signed a series of other agreements to boost its cancer pipeline, including most recently a $685m license deal for an immuno-oncology drug developed by Argenx.
-
AbbVie boosts immuno-oncology pipeline with $685m Argenx deal
Buys rights to immuno-suppressive antibody and will fund further research. Small Belgian biotech Argenx has scored a $685m licensing deal with AbbVie for an immuno-oncology candidate still in preclinical ... AbbVie has also agreed to fund further
More from news
Approximately 4 fully matching, plus 2 partially matching documents found.
Latest Intelligence
-
Deal Watch April 2016
CytomX leads. Argenx undertakes R&D until IND, AbbVie thereafter it option exercised. ... However the argenx deal is an option not a license and has lower royalty rates.
More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.
Latest from PMHub
-
Welcoming analytics-driven digital marketing agency closerlook to the Fishawack Health pack
The company works with a range of innovative biopharma companies including UCB, Novo Nordisk, Astellas, Akebia, TerSera Therapeutics, Zogenix, BioMarin, and argenx.
More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.
Subscribe to our email news alerts
- AstraZeneca and Daiichi Sankyo share positive results from phase 3 breast cancer study
- ICR and Merck renew strategic alliance for development of new cancer drugs
- DeepMind’s AI tool classifies effects of mutations in genetic diseases
- CDC awards over $23m to Johns Hopkins Center for Health Security project
- Looking to start activity on a currently unpromoted pharmaceutical brand?
- Considering a portfolio review?
No results were found
PMHub
Research Partnership
Research Partnership, an Inizio Advisory Company, is a world-leading custom and syndicated global insights partner for health and life science...
Latest intelligence
- The importance of accelerating clinical trial diversity
- Diversity shouldn’t be an afterthought – it’s an investment in the credibility of scientific endeavour...
- Digital Opinion Leaders: The Role of Influencers in Medical Communications
- There are many informed, knowledgeable HCPs who talk about a disease state online, but not all of them are influencers. This paper explores who digital opinion leaders are and how...
- Creating Hope Though Action – World Suicide Prevention Day
- At Mednet Group, we believe that actions speak louder than words. That's why we're getting behind this year's Suicide Prevention Day campaign of 'creating hope through action'....
